Gene expression signatures of a preclinical mouse model during colorectal cancer progression under low-dose metronomic chemotherapy


  • H. Ho-Xuan
  • G. Lehmann
  • P. Glazar
  • F. Gypas
  • N. Eichner
  • K. Heizler
  • H.J. Schlitt
  • M. Zavolan
  • N. Rajewsky
  • G. Meister
  • C. Hackl


  • Cancers


  • Cancers 13 (1): 49


  • Understanding the molecular signatures of colorectal cancer progression under chemotherapeutic treatment will be crucial for the success of future therapy improvements. Here, we used a xenograft-based mouse model to investigate, how whole transcriptome signatures change during metastatic colorectal cancer progression and how such signatures are affected by LDM chemotherapy using RNA sequencing. We characterized mRNAs as well as non-coding RNAs such as microRNAs, long non-coding RNAs and circular RNAs in colorectal-cancer bearing mice with or without LDM chemotherapy. Furthermore, we found that circZNF609 functions as oncogene, since over-expression studies lead to an increased tumor growth while specific knock down results in smaller tumors. Our data represent novel insights into the relevance of non-coding and circRNAs in colorectal cancer and provide a comprehensive resource of gene expression changes in primary tumors and metastases. In addition, we present candidate genes that could be important modulators for successful LDM chemotherapy.